Does targeted radioisotope therapy treat neuroblastoma?

The treatment combines a targeting molecule with a radioisotope. After it is given, the targeting part seeks cells with a matching feature and delivers radiation close to those cells. This can help treat disease that has spread or returned, but it is not suitable for every neuroblastoma.

Your team may review scans, laboratory results, previous treatments, kidney and liver function, blood counts, and the target shown by specialised imaging. The plan may involve more than one treatment visit and monitoring afterwards. Side effects can include tiredness, nausea, changes in blood counts, or effects on organs that clear the medicine.

Ask the neuroblastoma team whether the tumour has the relevant target and whether targeted radioisotope therapy fits the current treatment goal. Bring a list of medicines, supplements, allergies, previous cancer treatments, and any kidney or blood-count concerns. The team can explain preparation, radiation-safety instructions, contraception or pregnancy precautions where relevant, and how follow-up scans will be arranged.

Contact the treating team promptly for fever, repeated vomiting, unusual bleeding or bruising, reduced urine, severe weakness, confusion, or new breathing difficulty during or after treatment. Seek emergency help for severe breathing trouble, fainting, or a rapidly worsening condition. Use the contact instructions supplied by the hospital because monitoring needs can differ between treatment plans.

What target does my tumour show, and how was it checked? What is the aim of this treatment for me? How will my blood counts and kidney function be monitored? Which symptoms should make me call the hospital? What medicines, food, activity, or contact precautions apply after treatment?